Paul Choi
Stock Analyst at Goldman Sachs
(3.22)
# 1,026
Out of 5,172 analysts
106
Total ratings
50.75%
Success rate
0.98%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $8.10 | +48.15% | 4 | Feb 10, 2026 | |
| VERA Vera Therapeutics | Maintains: Buy | $55 → $95 | $40.53 | +134.39% | 1 | Dec 19, 2025 | |
| CYTK Cytokinetics | Upgrades: Buy | $55 → $95 | $61.70 | +53.97% | 3 | Dec 19, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $44 → $50 | $65.30 | -23.43% | 8 | Nov 5, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $55 → $100 | $68.54 | +45.90% | 7 | Oct 31, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $55 | $46.08 | +19.36% | 2 | Oct 29, 2025 | |
| ARVN Arvinas | Downgrades: Sell | $8 → $6 | $10.94 | -45.16% | 4 | Oct 15, 2025 | |
| LNTH Lantheus Holdings | Downgrades: Neutral | $110 → $77 | $76.43 | +0.75% | 2 | Oct 8, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Neutral | $20 | $29.06 | -31.18% | 1 | Sep 25, 2025 | |
| EXEL Exelixis | Initiates: Buy | $47 | $41.27 | +13.88% | 1 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $7 → $12 | $14.49 | -17.18% | 9 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $3 | $17.62 | -82.97% | 4 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $8 | $0.42 | +1,793.94% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $5 | $11.21 | -55.40% | 10 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $52 | $54.94 | -5.35% | 2 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $9.10 | +130.77% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $2.55 | +17.65% | 9 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $221.43 | +1.61% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $13.82 | +37.48% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $5.00 | +280.00% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.47 | +1,600.68% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $8.93 | +1,803.70% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $6.12 | +30.72% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $127.68 | +5.73% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $72.22 | +315.40% | 2 | Mar 30, 2020 |
REGENXBIO
Feb 10, 2026
Maintains: Neutral
Price Target: $14 → $12
Current: $8.10
Upside: +48.15%
Vera Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $95
Current: $40.53
Upside: +134.39%
Cytokinetics
Dec 19, 2025
Upgrades: Buy
Price Target: $55 → $95
Current: $61.70
Upside: +53.97%
PTC Therapeutics
Nov 5, 2025
Maintains: Sell
Price Target: $44 → $50
Current: $65.30
Upside: -23.43%
BridgeBio Pharma
Oct 31, 2025
Maintains: Buy
Price Target: $55 → $100
Current: $68.54
Upside: +45.90%
Kiniksa Pharmaceuticals International,
Oct 29, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $46.08
Upside: +19.36%
Arvinas
Oct 15, 2025
Downgrades: Sell
Price Target: $8 → $6
Current: $10.94
Upside: -45.16%
Lantheus Holdings
Oct 8, 2025
Downgrades: Neutral
Price Target: $110 → $77
Current: $76.43
Upside: +0.75%
Edgewise Therapeutics
Sep 25, 2025
Initiates: Neutral
Price Target: $20
Current: $29.06
Upside: -31.18%
Exelixis
Sep 17, 2025
Initiates: Buy
Price Target: $47
Current: $41.27
Upside: +13.88%
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $14.49
Upside: -17.18%
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $17.62
Upside: -82.97%
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $0.42
Upside: +1,793.94%
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $11.21
Upside: -55.40%
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $54.94
Upside: -5.35%
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $9.10
Upside: +130.77%
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $2.55
Upside: +17.65%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $221.43
Upside: +1.61%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $13.82
Upside: +37.48%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $5.00
Upside: +280.00%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.47
Upside: +1,600.68%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $8.93
Upside: +1,803.70%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $6.12
Upside: +30.72%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $127.68
Upside: +5.73%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $72.22
Upside: +315.40%